This is an ASCO Meeting Abstract from the 2008 ASCO Annual Meeting. This abstract does not include a full text component.

Induction therapy of toripalimab combined with docetaxel and cisplatin in locally advanced hypopharyngeal squamous cell carcinoma (HPSCC): A single-arm, phase II clinical trial. Prospective study of ...

Patients with previously treated advanced non-small cell lung cancer had similar overall survival (OS) with docetaxel and nab-paclitaxel (Abraxane), but the latter improved progression-free survival ...

To help oncology providers better understand drug mechanisms of action, and the economic implications of their use. Nab-paclitaxel (Abraxane) is an alternative form of the drug where paclitaxel is ...

New data demonstrate that nanoparticle albumin-bound (nab)-paclitaxel can elicit a favourable tumour response in patients with metastatic urothelial cancer that has progressed on first-line ...

Final results from a routine-practice comparison of taxane agents showed that the drugs offered comparable safety and efficacy in advanced HER2-positive breast cancer. Median progression-free survival ...

• Abraxis BioScience Inc., of Los Angeles, will begin enrollment in two Phase I/II clinical trials to investigate the use of its nab-docetaxel (ABI-008), an albumin-bound chemotherapeutic for the ...